<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02122601</url>
  </required_header>
  <id_info>
    <org_study_id>LG-HACL013</org_study_id>
    <nct_id>NCT02122601</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Safety and Efficacy of Retreatment With Intra-articular LBSA0103 Injections in the Patients With Osteoarthritis of the Knee</brief_title>
  <official_title>An Open-label, Single Arm, Multi-center, Phase 3 Study to Evaluate the Safety and Efficacy of Retreatment With Intra-articular LBSA0103 Injections in the Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of LBSA0103 (BDDE cross-linked sodium hyaluronate gel) when&#xD;
      it is administered for the second time 26 weeks after its first administration in patients&#xD;
      with osteoarthritis of the knee.&#xD;
&#xD;
      The Safety and efficacy of 26weeks after its first administration will be also evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events for 13 weeks after the first and second administration</measure>
    <time_frame>Week 13 from each baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local reactions at injection site after the first and second administration</measure>
    <time_frame>Week 13 from each baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events during total clinical study period</measure>
    <time_frame>0, 13, 26, 39 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>0, 13, 26, 39 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory exam</measure>
    <time_frame>0, 13, 26, 39 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Weight-bearing pain (100mm-VAS) from baseline</measure>
    <time_frame>0, 13, 26, 39 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of WOMAC-likert assessment: Pain, Function, stiffness, Total score from baseline</measure>
    <time_frame>0, 13, 26, 39 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Patient Global Assessment (100mm-VAS) from baseline</measure>
    <time_frame>0, 13, 26, 39 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Investigator Global Assessment (100mm-VAS) from baseline</measure>
    <time_frame>0, 13, 26, 39 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of rest pain(100mm-VAS) from baseline</measure>
    <time_frame>0, 13, 26, 39 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of night pain(100mm-VAS) from baseline</measure>
    <time_frame>0, 13, 26, 39 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of motion pain(100mm-VAS) from baseline</measure>
    <time_frame>0, 13, 26, 39 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical assessment: swelling on knee joint, tenderness on pressure and the range of motion of knee joint</measure>
    <time_frame>0, 13, 26, 39 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Subjects who took the Rescue Medicine (ACETAMINOPHEN REGIMEN) and Total Consumption</measure>
    <time_frame>0, 13, 26, 39 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate of subjects who showed a reduction by at least 20 mm or an improvement by at least 40% in the Weight-bearing pain (100 mmVAS)</measure>
    <time_frame>13, 26, 39 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMERACT-OARSI responder rate</measure>
    <time_frame>13, 26, 39 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Osteoarthritis of Knee</condition>
  <arm_group>
    <arm_group_label>LBSA0103</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>single arm , LBSA0103 only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LBSA0103 (BDDE cross-linked sodium hyaluronate gel)</intervention_name>
    <arm_group_label>LBSA0103</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A patient diagnosed with one or both knee osteoarthritis based on the clinical&#xD;
             diagnosis criteria of the American College of Rheumatology (ACR) (there should be knee&#xD;
             pain and in addition, at least three of the following six conditions have to be&#xD;
             satisfied: 1. Over 50 years of age 2. Less than 30 minutes of morning stiffness 3.&#xD;
             Crepitus on active motion 4 Bony tenderness 5. Bony enlargement 6. No palpable warmth&#xD;
             of synovium)&#xD;
&#xD;
          2. Adult male and female patients of age 40 or above diagnosed with knee osteoarthritis&#xD;
             with the Kellgren &amp; Lawrence Grade of I - III by x-ray within 6 months before the&#xD;
             screening visit (based on -2 weeks) or by x-ray at the screening visit&#xD;
&#xD;
          3. A patient who has at least one knee with a weight-bearing pain value of 40 mm or more&#xD;
             when weight-bearing pain (100 mm-VAS) is measured&#xD;
&#xD;
          4. A patient taking aspirin at a low dose (300 mg or less per day) who is willing to take&#xD;
             aspirin constantly at the same dose until the clinical study is completed and can&#xD;
             refrain from taking aspirin within 24 hours before each visit.&#xD;
&#xD;
          5. A patient who can walk without depending on a walking aid such as walker, cane, etc.&#xD;
             but if the patient has been using a walking aid on a daily basis from six months ago,&#xD;
             the patient assessment can be conducted while including the walking aid and the&#xD;
             walking aid must be used in the same way until the study is completed.&#xD;
&#xD;
          6. A patient who can understand the meanings of an efficacy measurement questionnaire&#xD;
             well and complete it&#xD;
&#xD;
          7. A patient who heard an explanation about the purpose, method, effects, etc. of the&#xD;
             clinical study and whose informed consent form has been signed by him/herself or&#xD;
             subject's representative&#xD;
&#xD;
          8. A patient who falls under one of the following four cases&#xD;
&#xD;
               -  Patients who are surgically infertile&#xD;
&#xD;
               -  Post-menopausal women who are above 45 years of age and 2 years after the last&#xD;
                  menstruation&#xD;
&#xD;
               -  Fertile premenopausal female patients or male patients without having a surgical&#xD;
                  sterilization who have agreed to use at least two birth control methods&#xD;
                  (including one of barrier methods) for at least 13 weeks after the administration&#xD;
                  of the last investigational product to avoid pregnancy&#xD;
&#xD;
                    -  Barrier methods: Condom, Diaphragm, Cervical cap(Pessary), Spermicide&#xD;
&#xD;
                    -  Hormonal methods: Pills, Injection(Depot), Skin patch, Hormonal&#xD;
                       implant(Implanon), Vaginal ring&#xD;
&#xD;
                    -  Intrauterine Devices(IUDs): Cooper IUD(Loop), Hormonal IUD(Mirena)&#xD;
&#xD;
                    -  Natural methods: Basic body temperature, Ovulation period, Coitus&#xD;
                       interruptus, Abstinent&#xD;
&#xD;
          9. A patient who discontinued analgesics, NSAIDs, condroichin sulfate/glucosamine and&#xD;
             physical therapy or oriental medical treatment (acupuncture, cubbing therapy, moxa&#xD;
             treatment) within 2 weeks before the administration (washout period) and has a will to&#xD;
             discontinue them from the screening visit of the study to the end (however, 300 mg&#xD;
             less per day of aspirin and acetaminophen, a rescue therapy, can be taken)&#xD;
&#xD;
         10. A patient who didn't take any analgesic including aspirin and acetaminophen within 24&#xD;
             hours before the administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Body mass index &gt; 32&#xD;
&#xD;
          2. A patient with rheumatoid arthritis, or other inflammatory or metabolic arthritis&#xD;
&#xD;
          3. A patient with infection or severe inflammation at the joint like septic arthritis&#xD;
&#xD;
          4. A patient with infection or skin disease at the site of administration&#xD;
&#xD;
          5. A patient with secondary knee osteoarthritis caused by ochronosis, hemochromatosis,&#xD;
             systemic disease, etc.&#xD;
&#xD;
          6. A patient with a very painful musculoskeletal disease such as Sudek's atrophy, Paget's&#xD;
             disease, or spinal disc herniation&#xD;
&#xD;
          7. A poly-artricular patient with a severe osteoarthritis symptom at other site (e.g.,&#xD;
             hip joint, etc.) which can have an effect on the assessment of the pain for knee joint&#xD;
&#xD;
          8. Patients diagnosed with knee osteoarthritis with the Kellgren &amp; Lawrence Grade of IV&#xD;
             in X-ray within 6 months before the screening visit (based on -2 weeks) or X-ray at&#xD;
             the screening visit&#xD;
&#xD;
          9. A patient showing a clear loss in the joint space of patello-femoral joint (PFJ) in&#xD;
             X-ray&#xD;
&#xD;
         10. A patient who took following drug before the administration of investigational product&#xD;
             (baseline visit):&#xD;
&#xD;
               -  A patient who had HA at the target knee joint within the last 6 months&#xD;
&#xD;
               -  A patient who was given an intra-articular knee joint injection with steroidal&#xD;
                  agent within the last 3 months&#xD;
&#xD;
               -  A patient who used steroidal agent systemically by oral administration within the&#xD;
                  last 1 month (However, except for inhalant)&#xD;
&#xD;
         11. A patient with moderate to severe joint effusion which was found to be positive&#xD;
             through patella tap test, etc.&#xD;
&#xD;
         12. A patient with alcoholism and alcoholic liver disease&#xD;
&#xD;
         13. A patient with a serious heart disease or hepatic and renal dysfunction or a patient&#xD;
             who showed the following laboratory test value:&#xD;
&#xD;
               -  AST, ALT ≥ 3 times the upper limit of normal range&#xD;
&#xD;
               -  Serum creatinine &gt; 2mg/dl&#xD;
&#xD;
         14. A patient who had a surgical procedure including arthroscopy on the target knee within&#xD;
             the last 1 year (In case of a patient who had a history of joint surgery on other knee&#xD;
             or hip joint, the patient shall be excluded if the assessment of the target knee is&#xD;
             likely to be affected by that. )&#xD;
&#xD;
         15. A patient who has a history of knee replacement surgery on the target knee joint&#xD;
&#xD;
         16. A patient who does highly intensive aerobic exercise or heavy anaerobic exercise such&#xD;
             as running or weight training which can have an effect on knee joint.&#xD;
&#xD;
         17. A patient who needs to use an anticoagulant agent concurrently (However, except for&#xD;
             aspirin of 300 mg or less per day)&#xD;
&#xD;
         18. A patient who is mentally ill or can't understand the purpose and method of this&#xD;
             clinical study&#xD;
&#xD;
         19. A patient who shows hypersensitivity reaction to the investigational product of this&#xD;
             clinical study&#xD;
&#xD;
         20. A patient who is participating in other clinical study after having enrolled in this&#xD;
             study, or participated in other clinical study within 1 month before the enrollment in&#xD;
             this clinical study&#xD;
&#xD;
         21. A patient who is considered to have a difficulty undergoing the clinical study at the&#xD;
             discretion of the Principal Investigator&#xD;
&#xD;
         22. A patient who was given one of the following drugs based on the day of administration:&#xD;
&#xD;
               -  A patient who was given anesthetic within the last 48 hours&#xD;
&#xD;
               -  A patient who took analgesics including acetaminophen and aspirin within the last&#xD;
                  24 hour&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>April 16, 2014</study_first_submitted>
  <study_first_submitted_qc>April 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2014</study_first_posted>
  <last_update_submitted>September 7, 2015</last_update_submitted>
  <last_update_submitted_qc>September 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

